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ECONOMIC ASSESSMENT OF A PROPHYLACTIC 
TREATMENT OF RECURRENCE OF ISCHEMIC 
ACCIDENTS BY LYSINE ACETYLSALICYLATE
Marissal JP, Selke B, Lebrun T
CRESGE, Lille, France
Despite its low cost and its proven efficacy in prevention
of recurrence of ischemic events, acetylsalicylic acid is a
strategy not used in France as frequently as it should be.
OBJECTIVE: In order to convince practitioners and pub-
lic authorities, we provide a cost-effectiveness analysis
(CEA) of lysine acetylsalicylate (LA) 300 mg as compared
to “do nothing.” 
METHODS: We used Garber and Phelps’s specification
of CEA. Efficacy data were derived from the Antiplatelet
Trialists’ Collaboration meta-analysis. We used French
data sources to estimate the cost of the prophylactic treat-
ment, the cost of treatment-related side effects, and the
cost of nonfatal events to be prevented (ischemic stroke,
myocardial infarction). The perspective taken into ac-
count for this CEA is that of the French Social Security
system.
RESULTS: The results presented in the above table pro-
vide economic evidence of the interest of lysine acetylsali-
cylate in preventing ischemic accidents since the benefits
produced by the prophylactic treatment almost exceed
the costs induced by this strategy.
CONCLUSION: As a consequence, such negative net
costs induce savings for the Social Security system. There-
fore, the prescription of acetylsalicylic acid and, in partic-
ular, lysine acetylsalicylate is medically effective and eco-
nomically efficient.
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OUTCOME OF ACUTE MYOCARDIAL 
INFARCTION PATIENTS WITH MAXIMAL 
INDIVIDUAL THERAPY (MITRA-STUDY)
Dommke C, Schiele R, Fischer F, Wienbergen H,
Voigtländer T, Glunz HG, Berg G, Gieseler U,
Lauterbach KW, Senges J
Herzzentrum Ludwigshafen; Universität Cologne, for the 
MITRA Study Group, Cologne, Germany
Drugs improving prognosis in acute myocardial infarc-
tion (AMI) are underused in clinical practice, despite es-
tablished therapy from randomized trials.
METHODS:  MITRA (Maximal Individual TheRapy in
Acute myocardial infarction) is a AMI registry of 54 hos-
pitals in southwest Germany. The aim is a more frequent
use of therapies improving prognosis. In the MITRA-1
study (6/94 to 1/97) the use of thrombolysis or PTCA, as-
pirin, beta blocker, or ACE-inhibitor was increased. The
ongoing MITRA-2 study (6/98 to 6/99) is aimed at im-
proving the use of CSE inhibitors to lower cholesterol af-
ter AMI, and includes a cost-utility analysis.
RESULTS: The use of all four therapy forms increased
during the study, especially with beta blocker and ACE
inhibitor. This was associated with a significant decrease
in hospital mortality (	20%).
CONCLUSION: In clinical practice, many AMI patients
do not adequately receive prognostic therapy. In the
MITRA-1 study, the use of prognostic therapy was mark-
edly reduced, as was the outcome. In the ongoing
MITRA-2 study, the additional effect of an increased use
of cholesterol reduction (CSE inhibitor) is being evalu-
ated, together with a cost-utility analysis.
ECONOMIC AND OUTCOMES STUDY RESULTS 
FOR MENTAL HEALTH
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ROAD TRAFFIC ACCIDENTS ARE ASSOCIATED 
WITH BENZODIAZEPINE USE
Barbone F2, McMahon AD1, Davey P1, Morris AD,
McDevitt DG, MacDonald TM1
1Medicines Monitoring Unit (MEMO), University of Dundee, 
Ninewells Hospital & Medical School, Dundee, Scotland,
2Chair of Hygiene and Epidemiology, DPMSC, University of 
Udine, Italy
BACKGROUND: Psychomotor studies suggest that psy-
choactive drugs impair driving skills. We have examined
the association between the use of psychoactive drugs
and road traffic accidents (RTA).
METHODS: We carried out a case-crossover study of
drivers 18 years, resident in Tayside, Scotland, and who
experienced a first road traffic accident recorded by Tay-
side Police between 1 August 1992 and 30 June 1994.
Each driver had used one of the following drugs: tricyclic
antidepressant (TCA), selective serotonin reuptake inhibi-
tor (SSRI), benzodiazepines, or other psychotropics, be-
Cost-effectiveness ratios (1996 US$)
Endpoint
Qualifying event MI Ischemic stroke
Unstable angina 	5,703 190,711*
Prior MI 	15 	37
Prior ischemic stroke 	610 	176
Stable angina 4,375 15,749*
*Insignificant difference in efficacy between LA and placebo.
MITRA-1
Pilot
phase
Study
phase 1
Study
phase 2 P
6 mo 1 yr 1 yr
n  6068 1298 2678 2062
Lysis and/or PTCA 55% 58% 60% 0.003
Aspirin 88% 94% 96% 0.001
Beta blocker 33% 55% 62% 0.001
ACE inhibitor 16% 58% 63% 0.001
Hospital mortality 16.3% 16.1% 13.1% 0.005
